SEARCH

SEARCH BY CITATION

References

  • Commission on Classification and Terminology of the International League against Epilepsy. (1989) Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30:389399.
  • Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI. (2002) Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. Stat Med 21:371387.
  • Caldwell PH, Murphy SB, Butow PN, Craig JC. (2004) Clinical trials in children. Lancet 364:803811.
  • Caraballo R, Tripoli J, Escobal L, Cersosimo R, Tenembaum S, Palacios C, Fejerman N. (1998) Ketogenic diet: efficacy and tolerability in childhood intractable epilepsy. Rev Neurol 26:6164.
  • Caraballo RH, Cersosimo RO, Sakr D, Cresta A, Escobal N, Fejerman N. (2005) Ketogenic diet in patients with Dravet syndrome. Epilepsia 46:15391544.
  • Ceulemans BP, Claes LR, Lagae LG. (2004) Clinical correlations of mutations in the SCN1A gene: from febrile seizures to severe myoclonic epilepsy in infancy. Pediatr Neurol 30:236243.
  • Chiron C, Marchand MC, Tran A, Rey E, D'athis P, Vincent J, Dulac O, Pons G. (2000) Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 356:16381642.
  • Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. (2001) De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 68:13271332.
  • Diener W, Sorni M, Ruile S, Rude P, Kruse R, Becker E, Bork K, Berg PA. (1998) Panniculitis due to potassium bromide. Brain Dev 20:8387.
  • Dravet C. (1978) Les epilepsies graves de l'enfant. Vie Méd 8:543548.
  • Dravet C, Bureau M, Guerrini R, Giraud N, Roger J. (1992) Severe myoclonic epilepsy in infants. In RogerJ, BureauM, DravetC, DreifussFE, PerretA, WolfP (Eds) Epileptic syndromes in infancy, children and adolescence. John Libbey & Company Ltd, London , pp. 7588.
  • Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. (2005) Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv Neurol 95:71102.
  • Ernst JP, Doose H, Baier WK. (1988) Bromides were effective in intractable epilepsy with generalized tonic-clonic seizures and onset in early childhood. Brain Dev 10:385388.
  • Fejerman N, Caraballo R, Cersosimo R. (2005) Ketogenic diet in patients with Dravet syndrome and myoclonic epilepsies in infancy and early childhood. Adv Neurol 95:299305.
  • Freedman B. (1987) Scientific value and validity as ethical requirements for research: a proposed explication. IRB 9:710.
  • Giraud C, Tran A, Rey E, Vincent J, Treluyer JM, Pons G. (2004) In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 32:12791286.
  • Goldsmith J, Mcknight C, Dickson S, Heenan M, Berezowski R. (2004) Miconazole and clobazam; a useful interaction in Dravet's syndrome? Arch Dis Child 89:89.
  • Greenland S. (1998) Meta-analysis. In RothmanK, GreenlandS (Eds) Modern epidemiology. 3rd ed. Lippincott-Raven, pp. 643674.
  • Grosso S, Franzoni E, Iannetti P, Incorpora G, Cardinali C, Toldo I, Verrotti A, Caterina Moscano F, Lo Faro V, Mazzone L, Zamponi N, Boniver C, Spalice A, Parisi P, Morgese G, Balestri P. (2005a) Efficacy and safety of topiramate in refractory epilepsy of childhood: long-term follow-up study. J Child Neurol 20:893897.
  • Grosso S, Galimberti D, Farnetani MA, Cioni M, Mostardini R, Vivarelli R, Di Bartolo RM, Bernardoni E, Berardi R, Morgese G, Balestri P. (2005b) Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure 14:183189.
  • Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. (1998) Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39:508512.
  • Guerrini R, Pons G. (2000) Comparative study of the efficacy of stiripentol used in combination in severe myoclonic epilepsy in infancy (SMEI). A double-blind, multicenter, placebo-controlled phase III study. Università di Pisa – IRCCS Tella Maris, Via dei Giacinti, 256018 Calambrone (PISA) , Italy .
  • Gueyffier F, Boutitie F, Boissel JP, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry HM, Pocock S, Prineas R, Schron E. (1995) INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results. Therapie 50:353362.
  • Horn CS, Ater SB, Hurst DL. (1986) Carbamazepine-exacerbated epilepsy in children and adolescents. Pediatr Neurol 2:340345.
  • Hurst DL. (1990) Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia 31:397400.
  • Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J. (2001) Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 286:821830.
  • Kjaergard LL, Villumsen J, Gluud C. (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135:982989.
  • Kroll-Seger J, Portilla P, Dulac O, Chiron C. (2006) Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics 37:325329.
  • Labate A, Colosimo E, Gambardella A, Leggio U, Ambrosio R, Quattrone A. (2006) Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 15:214218.
  • Lambert PC, Sutton AJ, Abrams KR, Jones DR. (2002) A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol 55:8694.
  • Marson A, Ramaratnam S. (2003) Epilepsy. Clinical evidence. BMJ Publishing Group, London .
  • Mikaeloff Y, De Saint-Martin A, Mancini J, Peudenier S, Pedespan JM, Vallee L, Motte J, Bourgeois M, Arzimanoglou A, Dulac O, Chiron C. (2003) Topiramate: efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 53:225232.
  • Minakawa K. (1995) [Effectiveness of intravenous midazolam for the treatment of status epilepticus in a child with severe myoclonic epilepsy in infancy]. No To Hattatsu 27:498500.
  • Molina-Carballo A, Munoz-Hoyos A, Reiter RJ, Sanchez-Forte M, Moreno-Madrid F, Rufo-Campos M, Molina-Font JA, Acuna-Castroviejo D. (1997) Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years' experience. J Pineal Res 23:97105.
  • Nabbout R, Gennaro E, Dalla Bernardina B, Dulac O, Madia F, Bertini E, Capovilla G, Chiron C, Cristofori G, Elia M, Fontana E, Gaggero R, Granata T, Guerrini R, Loi M, La Selva L, Lispi ML, Matricardi A, Romeo A, Tzolas V, Valseriati D, Veggiotti P, Vigevano F, Vallee L, Dagna Bricarelli F, Bianchi A, Zara F. (2003) Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology 60:19611967.
  • Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, Del Portal LR. (2000) Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 9:590594.
  • Oguni H, Hayashi K, Oguni M, Mukahira A, Uehara T, Fukuyama Y, Umezu R, Izumi T, Hara M. (1994) Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia 35:11401145.
  • Oguni H, Hayashi K, Osawa M, Awaya Y, Fukuyama Y, Fukuma G, Hirose S, Mitsudome A, Kaneko S. (2005) Severe myoclonic epilepsy in infancy: clinical analysis and relation to SCN1A mutations in a Japanese cohort. Adv Neurol 95:103117.
  • Quilichini P, Chiron C, Ben-Ari Y, Gozlan H. (2006) Stiripentol, a putative antiepileptic drug enhances the duration of opening of GABAA receptor channels. Epilepsia 47: 704716.
  • Rantala H, Saukkonen AL, Remes M, Uhari M. (1999) Efficacy of five days' barbiturate anesthesia in the treatment of intractable epilepsies in children. Epilepsia 40:17751779.
  • Reynolds E. (2005) There is more to treatment of epilepsy than control of seizures. Lancet 365:1981.
  • Saito Y, Oguni H, Awaya Y, Hayashi K, Osawa M. (2001) Phenytoin-induced choreoathetosis in patients with severe myoclonic epilepsy in infancy. Neuropediatrics 32:231235.
  • Senn S. (2004) Individual response to treatment: is it a valid assumption? BMJ 329:966968.
  • Steinhoff BJ, Kruse R. (1992) Bromide treatment of pharmaco-resistant epilepsies with generalized tonic-clonic seizures: a clinical study. Brain Dev 14:144149.
  • Thanh TN, Chiron C, Dellatolas G, Rey E, Pons G, Vincent J, Dulac O. (2002) Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome). Arch Pediatr 9:11201127.
  • Tomson T, Forsgren L. (2005) Life expectancy in epilepsy. Lancet 365:557558.
  • Tran A, Rey E, Pons G, Rousseau M, D'athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, Lepage F, Levy RH. (1997) Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 62:490504.
  • Trevathan E. (2000) Epilepsy syndrome-specific anti-epileptic drug therapy for children. Lancet 356:16231624.
  • Yakoub M, Dulac O, Jambaque I, Chiron C, Plouin P. (1992) Early diagnosis of severe myoclonic epilepsy in infancy. Brain Dev 14:299303.